{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:08:14Z","timestamp":1789276094479,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,18]]},"DOI":"10.7759\/cureus.45489","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T19:21:22Z","timestamp":1695064882000},"source":"Crossref","is-referenced-by-count":15,"title":["Exploring Advancements in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review of Current Modalities and Future Prospects"],"prefix":"10.7759","author":[{"given":"Pranvera","family":"Hoxhaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meet Popatbhai","family":"Kachhadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udeept","family":"Sindhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya A","family":"Durve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J","family":"Auz Vinueza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvan","family":".","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwe H","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak C","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman  P","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.851613","article-title":"Potential of cellular therapy for ALS: current strategies and future prospects","volume":"10","author":"Lin TJ","year":"2022","unstructured":"Lin TJ, Cheng GC, Wu LY, Lai WY, Ling TY, Kuo YC, Huang YH. Potential of cellular therapy for ALS: current strategies and future prospects. Front Cell Dev Biol. 2022, 10:851613. 10.3389\/fcell.2022.851613","journal-title":"Front Cell Dev Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori P","year":"2020","unstructured":"Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020, 27:1918-29. 10.1111\/ene.14393","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111523","article-title":"Current state and future directions in the therapy of ALS","volume":"12","author":"Tzeplaeff L","year":"2023","unstructured":"Tzeplaeff L, Wilfling S, Requardt MV, Herdick M. Current state and future directions in the therapy of ALS. Cells. 2023, 12:1523. 10.3390\/cells12111523","journal-title":"Cells"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.12865\/CHSJ.44.01.16","article-title":"Diagnosis particularities of amyotrophic lateral sclerosis in an elderly patient","volume":"44","author":"Marcu IR","year":"2018","unstructured":"Marcu IR, Patru S, Bighea A. Diagnosis particularities of amyotrophic lateral sclerosis in an elderly patient. Curr Health Sci J. 2018, 44:92-6. 10.12865\/CHSJ.44.01.16","journal-title":"Curr Health Sci J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.10.023","article-title":"Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1","volume":"578","author":"Fumagalli E","year":"2008","unstructured":"Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol. 2008, 578:171-6. 10.1016\/j.ejphar.2007.10.023","journal-title":"Eur J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2196\/10099","article-title":"Patient-reported outcome of physical therapy in amyotrophic lateral sclerosis: observational online study","volume":"5","author":"Meyer R","year":"2018","unstructured":"Meyer R, Spittel S, Steinfurth L, et al.. Patient-reported outcome of physical therapy in amyotrophic lateral sclerosis: observational online study. JMIR Rehabil Assist Technol. 2018, 5:e10099. 10.2196\/10099","journal-title":"JMIR Rehabil Assist Technol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00231","article-title":"Alleviation of psychological distress and the improvement of quality of life in patients with amyotrophic lateral sclerosis: adaptation of a short-term psychotherapeutic intervention","volume":"9","author":"Oberstadt MC","year":"2018","unstructured":"Oberstadt MC, Esser P, Classen J, Mehnert A. Alleviation of psychological distress and the improvement of quality of life in patients with amyotrophic lateral sclerosis: adaptation of a short-term psychotherapeutic intervention. Front Neurol. 2018, 9:231. 10.3389\/fneur.2018.00231","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon G","year":"2002","unstructured":"Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002, 249:609-15. 10.1007\/s004150200071","journal-title":"J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.47.6_suppl_4.233s","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble A","year":"1996","unstructured":"Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996, 47:S233-41. 10.1212\/wnl.47.6_suppl_4.233s","journal-title":"Neurology"},{"key":"ref10","article-title":"Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz MP","year":"2018","unstructured":"Cruz MP. Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T. 2018, 43:25-8.","journal-title":"P T"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel S","year":"2022","unstructured":"Witzel S, Maier A, Steinbach R, et al.. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022, 79:121-30. 10.1001\/jamaneurol.2021.4893","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27569","article-title":"Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes","volume":"66","author":"Paganoni S","year":"2022","unstructured":"Paganoni S, Watkins C, Cawson M, et al.. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022, 66:136-41. 10.1002\/mus.27569","journal-title":"Muscle Nerve"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller TM","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, et al.. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022, 387:1099-110. 10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study","volume":"19","author":"Benatar M","year":"2022","unstructured":"Benatar M, Wuu J, Andersen PM, et al.. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022, 19:1248-58. 10.1007\/s13311-022-01237-4","journal-title":"Neurotherapeutics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.03.061","article-title":"Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model","volume":"298","author":"Li Y","year":"2015","unstructured":"Li Y, Guo Y, Wang X, et al.. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience. 2015, 298:12-25. 10.1016\/j.neuroscience.2015.03.061","journal-title":"Neuroscience"},{"key":"ref16","article-title":"Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing","volume":"38","author":"Cruz MP","year":"2013","unstructured":"Cruz MP. Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing. P T. 2013, 38:325-8.","journal-title":"P T"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0508-5","article-title":"Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial","volume":"14","author":"Smith R","year":"2017","unstructured":"Smith R, Pioro E, Myers K, et al.. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017, 14:762-72. 10.1007\/s13311-016-0508-5","journal-title":"Neurotherapeutics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S146949","article-title":"Physical therapy for individuals with amyotrophic lateral sclerosis: current insights","volume":"8","author":"Bello-Haas VD","year":"2018","unstructured":"Bello-Haas VD. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2018, 8:45-54. 10.2147\/DNND.S146949","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26292","article-title":"Impact of expiratory strength training in amyotrophic lateral sclerosis: results of a randomized, sham-controlled trial","volume":"59","author":"Plowman EK","year":"2019","unstructured":"Plowman EK, Tabor-Gray L, Rosado KM, et al.. Impact of expiratory strength training in amyotrophic lateral sclerosis: results of a randomized, sham-controlled trial. Muscle Nerve. 2019, 59:40-6. 10.1002\/mus.26292","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2020.03.013","article-title":"ALS: management problems","volume":"38","author":"Brent JR","year":"2020","unstructured":"Brent JR, Franz CK, Coleman JM 3rd, Ajroud-Driss S. ALS: management problems. Neurol Clin. 2020, 38:565-75. 10.1016\/j.ncl.2020.03.013","journal-title":"Neurol Clin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/17482968.2012.692382","article-title":"Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis","volume":"14","author":"K\u00f6rner S","year":"2013","unstructured":"K\u00f6rner S, Sieniawski M, Kollewe K, et al.. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013, 14:20-5. 10.3109\/17482968.2012.692382","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0853","article-title":"Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis","volume":"4","author":"K\u00fchnlein P","year":"2008","unstructured":"K\u00fchnlein P, Gdynia HJ, Sperfeld AD, Lindner-Pfleghar B, Ludolph AC, Prosiegel M, Riecker A. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008, 4:366-74. 10.1038\/ncpneuro0853","journal-title":"Nat Clin Pract Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2008.09.010","article-title":"Palliative treatment of dysphonia and dysarthria","volume":"42","author":"Cohen SM","year":"2009","unstructured":"Cohen SM, Elackattu A, Noordzij JP, Walsh MJ, Langmore SE. Palliative treatment of dysphonia and dysarthria. Otolaryngol Clin North Am. 2009, 42:107-21. 10.1016\/j.otc.2008.09.010","journal-title":"Otolaryngol Clin North Am"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-151240","article-title":"Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis","volume":"37","author":"Paganoni S","year":"2015","unstructured":"Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT. Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. NeuroRehabilitation. 2015, 37:53-68. 10.3233\/NRE-151240","journal-title":"NeuroRehabilitation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.262578","article-title":"Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1\u03b4 activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment","volume":"14","author":"Bissaro M","year":"2019","unstructured":"Bissaro M, Moro S. Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1\u03b4 activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural Regen Res. 2019, 14:2083-5. 10.4103\/1673-5374.262578","journal-title":"Neural Regen Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010029","article-title":"Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis","volume":"14","author":"Cho H","year":"2020","unstructured":"Cho H, Shukla S. Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals (Basel). 2020, 14:29. 10.3390\/ph14010029","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s7788","article-title":"Current and emerging treatments for amyotrophic lateral sclerosis","volume":"5","author":"Zoccolella S","year":"2009","unstructured":"Zoccolella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat. 2009, 5:577-95. 10.2147\/ndt.s7788","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"Elia AE","year":"2016","unstructured":"Elia AE, Lalli S, Monsurr\u00f2 MR, et al.. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016, 23:45-52. 10.1111\/ene.12664","journal-title":"Eur J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02143-w","article-title":"MSC-NTF (NurOwn\u00ae) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model","volume":"12","author":"Kaspi H","year":"2021","unstructured":"Kaspi H, Semo J, Abramov N, et al.. MSC-NTF (NurOwn\u00ae) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model. Stem Cell Res Ther. 2021, 12:72. 10.1186\/s13287-021-02143-w","journal-title":"Stem Cell Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06327-4","article-title":"Efficacy and safety of Lenzumestrocel (Neuronata-R\u00ae inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial","volume":"23","author":"Nam JY","year":"2022","unstructured":"Nam JY, Lee TY, Kim K, et al.. Efficacy and safety of Lenzumestrocel (Neuronata-R\u00ae inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. Trials. 2022, 23:415. 10.1186\/s13063-022-06327-4","journal-title":"Trials"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03903-3","article-title":"Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx\u00ae) in ALS patients: phase I\/IIa clinical trial results","volume":"21","author":"Gotkine M","year":"2023","unstructured":"Gotkine M, Caraco Y, Lerner Y, et al.. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx\u00ae) in ALS patients: phase I\/IIa clinical trial results. J Transl Med. 2023, 21:122. 10.1186\/s12967-023-03903-3","journal-title":"J Transl Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000517","article-title":"Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis","volume":"350","author":"Russ KB","year":"2015","unstructured":"Russ KB, Phillips MC, Wilcox CM, Peter S. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis. Am J Med Sci. 2015, 350:95-7. 10.1097\/MAJ.0000000000000517","journal-title":"Am J Med Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-2007-22607","article-title":"The role of augmentative communication devices in the medical management of ALS","volume":"22","author":"Brownlee A","year":"2007","unstructured":"Brownlee A, Palovcak M. The role of augmentative communication devices in the medical management of ALS. NeuroRehabilitation. 2007, 22:445-50. 10.3233\/NRE-2007-22607","journal-title":"NeuroRehabilitation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fresc.2023.1152043","article-title":"Noninvasive respiratory assistance as aid for respiratory care in neuromuscular disorders","volume":"4","author":"Graustein A","year":"2023","unstructured":"Graustein A, Carmona H, Benditt JO. Noninvasive respiratory assistance as aid for respiratory care in neuromuscular disorders. Front Rehabil Sci. 2023, 4:1152043. 10.3389\/fresc.2023.1152043","journal-title":"Front Rehabil Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721040-00003","article-title":"Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management","volume":"21","author":"Kurt A","year":"2007","unstructured":"Kurt A, Nijboer F, Matuz T, K\u00fcbler A. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs. 2007, 21:279-91. 10.2165\/00023210-200721040-00003","journal-title":"CNS Drugs"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-023-01354-7","article-title":"Acceptance and commitment therapy for people living with motor neuron disease: an uncontrolled feasibility study","volume":"9","author":"Gould RL","year":"2023","unstructured":"Gould RL, Rawlinson C, Thompson B, et al.. Acceptance and commitment therapy for people living with motor neuron disease: an uncontrolled feasibility study. Pilot Feasibility Stud. 2023, 9:116. 10.1186\/s40814-023-01354-7","journal-title":"Pilot Feasibility Stud"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00192","article-title":"The impact of cognitive and behavioral symptoms on ALS patients and their caregivers","volume":"10","author":"Caga J","year":"2019","unstructured":"Caga J, Hsieh S, Lillo P, Dudley K, Mioshi E. The impact of cognitive and behavioral symptoms on ALS patients and their caregivers. Front Neurol. 2019, 10:192. 10.3389\/fneur.2019.00192","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/182811-exploring-advancements-in-the-treatment-of-amyotrophic-lateral-sclerosis-a-comprehensive-review-of-current-modalities-and-future-prospects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:43Z","timestamp":1707509143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/182811-exploring-advancements-in-the-treatment-of-amyotrophic-lateral-sclerosis-a-comprehensive-review-of-current-modalities-and-future-prospects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.45489","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}